Jupiter Neurosciences (JUNS) said Thursday that it has entered into a partnership with Zina Biopharmaceuticals for an upcoming phase 2a clinical trial to evaluate Jupiter's Jotrol resveratrol-based platform in Parkinson's disease.
Zina will assist with trial design, regulatory strategy, and trial site selection, according to Jupiter.
The study has a primary objective of evaluating the safety and tolerability of Jotrol, with secondary endpoints to assess the drug's pharmacokinetics and pharmacodynamics, Jupiter said.
Jupiter also said it is exploring partnerships to look into Jotrol's potential for treating other neuroinflammatory and metabolic disorders, including Alzheimer's disease.
Shares of Jupiter were down more than 5% in recent trading.
Price: 1.15, Change: -0.07, Percent Change: -5.74
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.